



#13
Amend. B (see)
w/attach.
10/22/01
RESPONSE UNDER 37 CFR 1.116
EXPEDITED PROCEDURE
EXAMINING GROUP 1648

PATENT
Attorney Docket No. 204133

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Roelvink et al.

Application No. 09/617,569

Filed: July 17, 2000

For: ANTIGENIC COMPOUNDS AND METHODS

Group Art Unit: 1648

Examiner: S. Foley

RECEIVED

OCT 19 2001

TECH CENTER 1600/2900

RESPONSE TO OFFICE ACTION

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In response to the Office Action dated August 14, 2001, please enter the following amendments and consider the following remarks.

AMENDMENTS

IN THE SPECIFICATION:

On page 13, line 20, replace "heparin" with --integrin--.

IN THE CLAIMS:

Please cancel claims 7, 20, 41, and 42, and amend claims 1, 8, 9, 26, and 40 to read as follows:

- Sub. 21
B!
cont'd.
1. A complex comprising (a) a virion having a surface and a lumen and comprising viral capsid proteins, (b) at least one non-native ligand displayed on the surface, which at least one ligand recognizes an epitope present on an immune effector

CERTIFICATE OF MAILING

I hereby certify that this RESPONSE TO OFFICE ACTION (along with any documents referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.

October 12, 2001

Date

Peter Phillips